Skip to main content

Table 2 Comparison of oestrogen and progesterone receptor phenotypes with response in a neoadjuvant trial of tamoxifen versus letrozole

From: Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens

 

Letrozole

Tamoxifen

 

Phenotype

n

RR (%)

n

RR (%)

P

ER+/PgR+

54/85

64

33/81

41

0.005

ER+/PgR-

18/34

53

16/41

39

0.331

ER-/PgR+

2/4

50

2/2

100

NS

ER-/PgR-

1/12

8

0/16

0

NS

ErbB1 or 2+/ER+

15/17

88

4/19

21

0.0004

ErbB1 and 2-/ER+

55/101

54

42/100

42

0.08

ErbB1 or 2+/ER-

0/9

0

0/10

0

-

  1. ER, oestrogen receptor; NS, not significant; PgR, progesterone receptor; RR, response rate. Data from Ellis and coworkers [32].
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us